September 4, 2024:
A Big Ten Cancer Research Consortium (Big Ten CRC) study manuscript was published in Lung Cancer Journal on August 15, 2024. The article is titled, “Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.”
Congratulations to all co-authors and study teams whose hard work led to this publication.
August 12, 2024:
The Big Ten Cancer Research Consortium is happy to celebrate the research accomplishments of our members over the past year. Congratulations to all researchers and study teams whose hard work produced eight journal manuscripts and meeting abstracts between July 1, 2023, and June 30, 2024!
August 2, 2024:
The expansion of the Big Ten Conference on August 2 to include four new members creates an opportunity for growth of the Big Ten Cancer Research Consortium (Big Ten CRC). The Big Ten CRC has invited the new members of the athletic conference – the University of California at Los Angeles, the University of Oregon, the University of Southern California, and the University of Washington – to join the Big Ten CRC. Plans to expand the Big Ten CRC are proceeding.
July 24, 2024:
Daniel Isaac, DO, an Assistant Professor in the Division of Hematology and Oncology at Michigan State University College of Human Medicine, has been appointed to represent Michigan State University on the Big Ten Cancer Research Consortium Steering Committee.
July 23, 2024:
The Big Ten Cancer Research Consortium (Big Ten CRC) Population Science Clinical Trial Working Group has received $5,000 of a $90,000 donation to be used for collaborative research regarding rural cancer survivorship. The donation is the second given to the Big Ten CRC by the Verna Mae Jessen Trust, with the first donation of $100,000 given in 2022.
July 15, 2024:
The Big Ten Cancer Research Consortium has launched new episodes for each of our podcast series: “Bridging the Gap” and “AYA Cancer in Focus.”
July 12, 2024:
Mark Burkard, MD, PhD, has been named director of Holden Comprehensive Cancer Center at the University of Iowa, and will begin his new role on October 1, pending approval from the Iowa Board of Regents. He will also begin as professor in the Department of Internal Medicine in the Division of Hematology, Oncology, and Blood Marrow Transplantation in the Carver College of Medicine.
May 29, 2024:
A Big Ten Cancer Research Consortium (Big Ten CRC) study was published in Nature Communications on February 1, 2024. The article is titled, “Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.”
May 28, 2024:
Monika Joshi, MD, MRCP, has been re-appointed as the chief scientific officer of the Big Ten Cancer Research Consortium.
May 15, 2024:
The Big Ten Cancer Research Consortium (Big Ten CRC) is set to participate in the American Society of Clinical Oncology® (ASCO) 2024 Annual Meeting in Chicago from May 31 to June 4. During the event, three Big Ten CRC studies will be presented, working group meetings will take place, and the Big Ten CRC will host a joint reception with Hoosier Cancer Research Network (HCRN). The Big Ten CRC will also be represented in the exhibit hall at HCRN’s booth, #37113.
© 2024 All rights reserved.
Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube